UBS Group AG Grows Position in Amicus Therapeutics, Inc. $FOLD

Key Points

• UBS Group AG raised its stake in Amicus Therapeutics by 240.5% in Q4, buying an additional 4,162,433 shares to hold 5,893,288 shares (~1.88% of the company) valued at about $83.92 million.
• Amicus shares trade around $14.49 (near a 12‑month high of $14.50) with a market cap of $4.55 billion; analysts' consensus rating is Hold with an average price target of $14.56.
• CEO Bradley L. Campbell sold 22,500 shares at an average price of $14.35 (≈$322,875), leaving him with 998,680 shares, and company insiders collectively own about 2.20% of the stock.

UBS Group AG raised its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 240.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,893,288 shares of the biopharmaceutical company's stock after purchasing an additional 4,162,433 shares during the quarter. UBS Group AG owned approximately 1.88% of Amicus Therapeutics worth $83,920,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Osaic Holdings Inc. lifted its holdings in Amicus Therapeutics by 450.1% during the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 3,358 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Amicus Therapeutics by 472.6% during the second quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 3,677 shares during the period. Farther Finance Advisors LLC increased its position in shares of Amicus Therapeutics by 2,651.5% during the fourth quarter. Farther Finance Advisors LLC now owns 1,871 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 1,803 shares during the period. GAMMA Investing LLC increased its position in shares of Amicus Therapeutics by 167.1% during the fourth quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 1,243 shares during the period. Finally, Strs Ohio bought a new stake in shares of Amicus Therapeutics during the first quarter valued at about $30,000.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $14.49 on Monday. The business's 50-day moving average price is $14.42 and its 200-day moving average price is $12.72. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $14.50. The stock has a market cap of $4.55 billion, a PE ratio of -181.13 and a beta of 0.48. The company has a quick ratio of 1.88, a current ratio of 2.84 and a debt-to-equity ratio of 1.43.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last posted its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.03). The company had revenue of $185.21 million during the quarter, compared to the consensus estimate of $185.00 million. Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The firm's revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter last year, the company posted $0.09 earnings per share. On average, equities analysts forecast that Amicus Therapeutics, Inc. will post 0.43 EPS for the current fiscal year.

Analysts Set New Price Targets

FOLD has been the topic of several analyst reports. Guggenheim cut Amicus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Amicus Therapeutics in a research report on Friday, March 27th. Jefferies Financial Group reiterated a "hold" rating and set a $14.50 price target (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Finally, Zacks Research cut Amicus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 26th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $14.56.

Insider Buying and Selling at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 22,500 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $14.35, for a total value of $322,875.00. Following the transaction, the chief executive officer directly owned 998,680 shares in the company, valued at approximately $14,331,058. This represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.20% of the company's stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics NASDAQ: FOLD is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company's lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.